Market Currents
More on Merck (MRK) Q3 earnings: FY2012 guidance narrowed to EPS of $3.78-$3.82 from...
-
Friday, October 26, 2012, 7:15 AM ETMore on Merck (MRK) Q3 earnings: FY2012 guidance narrowed to EPS of $3.78-$3.82 from $3.75-$3.85. Forgetting currency issues, revenue is expected at or near 2011 level. Singulair sales -55% Y/Y. Patent expires in Europe in Feb. and company expects declining sales there similar to what happened in the U.S. Januvia/Janumet sales +15%, Zetia/Vytorin sales -1%. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
